Methenolone Acetate is an oral form of methenolone, a dihydrotestosterone derivative created by Schering in the early 1960s. In the sports environment, it is considered a "soft" steroid. The editors analyze what is behind this reputation at the molecular level: how the substance binds to the androgen receptor, why it does not turn into estrogens, and how exactly it affects the synthesis of muscle protein.
The structure of the molecule and its consequences
Chemically, methenolone is 1-methyl-5α-androst-1-ene-17β-ol-3-one. Simply put, it is a molecule of dihydrotestosterone (DHT) to which a double bond has been added between the first and second carbon atoms and a methyl group in position 1. In the acetate form, a short acetic acid residue is attached to the 17β-hydroxyl group.
Each of these modifications makes pharmacological sense. Since the molecule is already "restored" at the 5α position, the enzyme 5-alpha-reductase cannot further modify it. Therefore, methenolone does not have an "enhanced" form in the skin or prostate, unlike testosterone, which is converted there into a much more active DHT.
The absence of the classical ring A with a double bond in position 4 means that the aromatase enzyme cannot convert methenolone to estrogens. This explains why the estrogenic effects characteristic of testosterone are not observed with its use - fluid retention and gynecomastia caused by excess estradiol.
It is fundamentally important that methenolone acetate does not have a 17α-alkyl group, which is present in most oral steroids (methandienone, stanozolol, oxandrolone). It is this group that protects oral steroids from destruction in the liver, but at the same time is associated with their hepatotoxicity. The oral activity of methenolone is associated with other features of the structure, and its price is low bioavailability.
| Structural element | What it changes |
|---|---|
| 5α-reduced skeleton (as in DHT) | Not a substrate for 5α-reductase |
| C1–C2 double bond | Alters the metabolic stability of the A ring |
| 1-methyl group | Slows down hepatic metabolism |
| 17β-acetate | Short ester form for oral administration |
| Absence of 17α-alkyl | Lower liver load but also lower bioavailability |
Binding to the androgen receptor
Like all anabolic-androgenic steroids, methenolone acts primarily through the androgen receptor (AR), an intracellular protein from the nuclear receptor family. In an inactive state, the receptor is in the cytoplasm in a complex with heat shock proteins. After binding the hormone, the receptor changes its conformation, detaches from these proteins and forms a dimer.
Acetate ester must be cleaved by esterases for the molecule to acquire full activity, because it is the free 17β-hydroxyl group that is involved in binding to the receptor pocket. This process happens quickly - in the intestinal wall, liver and blood.
Comparative studies of the relative affinity of anabolic steroids for the androgen receptor, in particular the work of Saartok et al. (1984), showed that different synthetic androgens differ significantly in their binding strength and that this strength does not always directly correspond to their anabolic activity in the body. For methenolone, we do not provide exact numbers because the data varies between fabrics and models.
An important nuance: the high "anabolic" reputation of drugs is often explained not only by the strength of binding, but also by what happens to the molecule in a specific tissue. For testosterone in the skin and prostate there is an "amplifier" in the form of 5α-reductase, but for methenolone there is no such amplification. Hence the relatively lower androgenic effect on these tissues in classical animal experiments.
At the same time, it is important not to overestimate this "separation". The androgen receptor in the muscle and in the hair follicle is the same protein. Therefore, a completely "anabolic" steroid without androgenic effects does not exist, and methenolone is no exception.
From receptor to protein synthesis
The "hormone-receptor" dimer penetrates into the nucleus and binds to specific areas of DNA - androgen-sensitive elements. Next, coactivator proteins are involved, and the transcription of target genes is enhanced. In skeletal muscle, these are genes responsible for the synthesis of contractile proteins, fiber growth, and regulation of energy metabolism.
The result is a positive nitrogen balance: the body retains more nitrogen than it excretes, which reflects the predominance of protein synthesis over its breakdown. Positive nitrogen balance was the key argument for the medical use of anabolic steroids in emaciated patients in the 1960s and 1970s.
In addition to direct effects on genes, androgens affect satellite cells — muscle stem cells that provide new nuclei for growing fibers. This mechanism is described in detail for testosterone in a review by Kicman (2008), and it is logical to assume that it applies to all androgen receptor agonists, but there are almost no separate studies specifically for methenolone in humans.
Another discussed mechanism is anti-catabolic. Androgens may compete with glucocorticoids for influencing the expression of genes associated with muscle protein breakdown. This effect has been convincingly demonstrated in animals and in the clinical setting of catabolic states, but its contribution to healthy humans is difficult to assess.
Finally, androgens stimulate erythropoiesis—the formation of red blood cells, in part through effects on erythropoietin and iron metabolism. Historically, methenolone was even used for some forms of anemia precisely because of this property.
How does the mechanism differ from testosterone
Testosterone is a “prohormone” in the tissue sense: it is converted to DHT or estradiol in different organs, and each of these metabolites has its own profile of action. Methenolone acts "as is", without such transformations. Therefore, its effects are easier to predict, but also lack the beneficial effects that estradiol provides.
In men, estradiol, formed from testosterone, is important for bone density, lipid metabolism, libido, and brain function. An androgen that is not aromatized, when suppressing its own testosterone, can cause a deficiency of estrogens with the corresponding consequences - this is often underestimated.
- Testosterone: aromatizes, turns into DHT, has a full spectrum of androgenic and estrogenic effects.
- Methenolone: does not aromatize, is not enhanced by 5α-reductase, acts only through the androgen receptor.
- 17α-alkylated oral steroids: high oral bioavailability but significantly higher hepatotoxicity.
In classical pharmacological models, the ratio of anabolic and androgenic activity was estimated by the weight gain of the levator ani muscle and prostate in castrated rats. Methenolone in these models had a favorable ratio, but Kicman (2008) emphasizes that such indicators are not well transferred to humans and do not guarantee safety.
The practical conclusion is simple: the "softness" of methenolone is relative and refers mainly to the absence of estrogenic effects. The rest of the consequences associated with the androgen receptor — suppression of the hormonal axis, lipid changes, virilization in women — persist.
Limits of the evidence base and risks
Most of what is known about methenolone acetate comes from animal experiments and clinical work from the 1960s to 1980s, which are not up to today's standards. There are no current randomized studies of efficacy and safety in healthy people, so many claims of "net growth" or "safety" are extrapolations.
Systematic reviews of the effects of nonmedical use of anabolic steroids, including a statement by the Endocrine Society (Pope et al., 2014), describe suppression of the hypothalamic-pituitary-gonadal axis, adverse lipid changes, and cardiac and psychiatric effects as common to this class of substances. There is no reason to believe that methenolone is completely free of these effects.
A separate risk is product quality. Original methenolone preparations have long been scarce, and the illegal market, according to analytical studies, often offers products with or without another active ingredient. So, the real mechanism of action of "tablets with the inscription methenolone" may be completely different.
Methenolone is included in Section S1 Anabolic Agents of the WADA Prohibited List and is prohibited in sport at all times. Its metabolites are determined by standard doping control methods.
Editorial conclusion
Methenolone acetate is a DHT derivative that acts directly through the androgen receptor, is not aromatized, and is not enhanced by 5α-reductase. This explains the absence of estrogenic effects and relatively lower androgenic effects in classical models.
The anabolic effect is realized through the standard path for androgens: activation of gene transcription, positive nitrogen balance, effect on satellite cells and erythropoiesis. There is nothing "unique" in the mechanism - only the metabolic fate of the molecule differs.
The perception of methenolone as a "safe" steroid is based on outdated data and extrapolation. Systemic risks of the anabolic steroid class persist, and the evidence base for healthy individuals is very limited.
To complete the picture, the editors advise you to read our materials about the oral bioavailability of methenolone acetate, about its effect on your own testosterone production, and about the myths surrounding this drug.
References
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502â521.
- Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100â2106.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341â375.
- Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem. 2003;40(Pt 4):321â356.
- Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57:411â434.
- Nieschlag E, Behre HM, Nieschlag S (eds). Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
- World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; updated every year.
